 |
budesonide |
|---|---|
| Trade Name | Nefecon |
| Orphan Indication | To slow the progression of immunoglobulin A nephropathy & delay kidney failure in patients affected by the disease |
| USA Market Approval | USA |
| USA Designation Date | 2010-05-17 00:00:00 |
| Sponsor | Calliditas Therapeutics AB;Wallingata 26b;Stockholm |
